Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.
Denda T, Sakai D, Hamaguchi T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Sunaga Y, Ziti-Ljajic S, Brillac C, Yoshino T. Denda T, et al. Among authors: takahashi s. Cancer Sci. 2019 Mar;110(3):1032-1043. doi: 10.1111/cas.13943. Epub 2019 Feb 22. Cancer Sci. 2019. PMID: 30657223 Free PMC article. Clinical Trial.
Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients.
Kato S, Andoh H, Gamoh M, Yamaguchi T, Murakawa Y, Shimodaira H, Takahashi S, Mori T, Ohori H, Maeda S, Suzuki T, Kato S, Akiyama S, Sasaki Y, Yoshioka T, Ishioka C; Tohoku Clinical Oncology Research and Education. Kato S, et al. Among authors: takahashi s. Oncology. 2012;83(2):101-7. doi: 10.1159/000339541. Epub 2012 Jul 9. Oncology. 2012. PMID: 22777333 Clinical Trial.
Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H, Shimodaira H, Gamoh M, Ando H, Isobe H, Suto T, Takahashi S, Kakudo Y, Amagai K, Mori T, Watanabe M, Yamaguchi T, Kato S, Ishioka C. Soeda H, et al. Among authors: takahashi s. Oncology. 2014;87(1):7-20. doi: 10.1159/000360989. Epub 2014 Jun 24. Oncology. 2014. PMID: 24968756 Clinical Trial.
Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Komatsu Y, Ishioka C, Shimada K, Yamada Y, Gamoh M, Sato A, Yamaguchi T, Yuki S, Morita S, Takahashi S, Goto R, Kurihara M. Komatsu Y, et al. Among authors: takahashi s. BMC Cancer. 2015 Sep 9;15:626. doi: 10.1186/s12885-015-1630-1. BMC Cancer. 2015. PMID: 26353772 Free PMC article. Clinical Trial.
DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.
Ouchi K, Takahashi S, Yamada Y, Tsuji S, Tatsuno K, Takahashi H, Takahashi N, Takahashi M, Shimodaira H, Aburatani H, Ishioka C. Ouchi K, et al. Among authors: takahashi m, takahashi n, takahashi h, takahashi s. Cancer Sci. 2015 Dec;106(12):1722-9. doi: 10.1111/cas.12827. Epub 2015 Nov 12. Cancer Sci. 2015. PMID: 26426205 Free PMC article.
CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Zhang X, Shimodaira H, Soeda H, Komine K, Takahashi H, Ouchi K, Inoue M, Takahashi M, Takahashi S, Ishioka C. Zhang X, et al. Among authors: takahashi m, takahashi h, takahashi s. Int J Clin Oncol. 2016 Dec;21(6):1091-1101. doi: 10.1007/s10147-016-1017-6. Epub 2016 Jul 19. Int J Clin Oncol. 2016. PMID: 27435270
Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis.
Okita A, Imai H, Takahashi M, Takahashi H, Umegaki S, Kawamura Y, Hiraide S, Ouchi K, Sato Y, Okada Y, Komine K, Saijo K, Takahashi S, Takahashi M, Shirota H, Ohori H, Gamoh M, Ishioka C. Okita A, et al. Among authors: takahashi m, takahashi h, takahashi s. Tohoku J Exp Med. 2018 Jun;245(2):123-129. doi: 10.1620/tjem.245.123. Tohoku J Exp Med. 2018. PMID: 29937450 Free article.
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Hamaguchi T, Denda T, Kudo T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Chiron M, Yoshino T. Hamaguchi T, et al. Among authors: takahashi s. Cancer Sci. 2019 Nov;110(11):3565-3572. doi: 10.1111/cas.14198. Epub 2019 Oct 21. Cancer Sci. 2019. PMID: 31520559 Free PMC article.
Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.
Takahashi S, Sakamoto Y, Denda T, Takashima A, Komatsu Y, Nakamura M, Ohori H, Yamaguchi T, Kobayashi Y, Baba H, Kotake M, Amagai K, Kondo H, Shimada K, Sato A, Yuki S, Okita A, Ouchi K, Komine K, Watanabe M, Morita S, Ishioka C. Takahashi S, et al. Cancer Sci. 2021 Apr;112(4):1567-1578. doi: 10.1111/cas.14841. Epub 2021 Feb 27. Cancer Sci. 2021. PMID: 33548159 Free PMC article. Clinical Trial.
11,110 results
You have reached the last available page of results. Please see the User Guide for more information.